Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

56.09 -0.63 (-1.11%)
Official Closing Price Updated: 6:30 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Market Whales and Their Recent Bets on NVO Options
 
Via Benzinga
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025. 
Via Benzinga
NVO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
S&P 500 Slips From Intraday Highs As Investors Lock In Profits After A Strong Week
The S&P 500 ended lower on Friday after setting fresh intraday records earlier in the session, as investors took profits following a strong week. 
Via Talk Markets
Topics Stocks Stocks / Equities
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
 
Via Benzinga
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Via The Motley Fool
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Why Eli Lilly Stock Topped the Market Today
Via The Motley Fool
Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?
Wall Street paused for a breather on Friday, with the S&P 500 index hovering around the flatline at midday trading in New York after a five-day rally that pushed the market to fresh record highs this... 
Via Benzinga
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Novo Nordisk Unusual Options Activity
 
Via Benzinga
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Novo Nordisk may have found a winner in amycretin. 
Via The Motley Fool
Allurion Catapults 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk
While the other companies are testing weight-loss drugs, Allurion has a different approach to obesity. 
Via Investor's Business Daily
Customers Bancorp, Twilio, Dana And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
The results also come as a relief following a selloff triggered by disappointing results from Novo’s CagriSema trial, which many deemed overblown. 
Via Stocktwits
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned. 
Via Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 inhibitors with potential for other diseases. 
Via Benzinga
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing good growth, while it is not too expensive. 
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
5 Stocks to Buy Now for Big Returns in 2025
Here are five stocks to buy now that could offer investors upside in 2025. 
Via The Motley Fool
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and placebo over 72 weeks. 
Via Benzinga
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs. 
Via Stocktwits
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
The price negotiations will take place in 2025 and go into effect in 2027 for a new list of 15 drugs. 
Via Investor's Business Daily
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.